Terms: = Leukemia AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750
131 results:
1. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
You L; Liu Y; Mai W; Xie W; Zhou D; Mao L; Chen L; Zhou X; Ma L; Zheng X; Wei J; Lou Y; Ye X; Tong H; Jin J; Meng H
Eur J Cancer; 2024 May; 202():113979. PubMed ID: 38471289
[TBL] [Abstract] [Full Text] [Related]
2. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
3. Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study.
Munshi L; Dumas G; Rochwerg B; Shoukat F; Detsky M; Fergusson DA; Ferreyro BL; Heffernan P; Herridge M; Magder S; Minden M; Patel R; Qureshi S; Schimmer A; Thyagu S; Wang HT; Mehta S
Intensive Care Med; 2024 Apr; 50(4):561-572. PubMed ID: 38466402
[TBL] [Abstract] [Full Text] [Related]
4. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract] [Full Text] [Related]
5. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract] [Full Text] [Related]
6. Acute Lymphoblastic leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Saygin C; Zhang P; Stauber J; Aldoss I; Sperling AS; Weeks LD; Luskin MR; Knepper TC; Wanjari P; Wang P; Lager AM; Fitzpatrick C; Segal JP; Gharghabi M; Gurbuxani S; Venkataraman G; Cheng JX; Eisfelder BJ; Bohorquez O; Patel AA; Umesh Nagalakshmi S; Jayaram S; Odenike OM; Larson RA; Godley LA; Arber DA; Gibson CJ; Munshi NC; Marcucci G; Ebert BL; Greally JM; Steidl U; Lapalombella R; Shah BD; Stock W
Blood Cancer Discov; 2024 May; 5(3):164-179. PubMed ID: 38150184
[TBL] [Abstract] [Full Text] [Related]
7. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
8. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU; Munir T; Moreno C; Owen C; Follows GA; Benjamini O; Janssens A; Levin MD; Robak T; Simkovic M; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Sinet P; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Kater AP
Lancet Oncol; 2023 Dec; 24(12):1423-1433. PubMed ID: 37944541
[TBL] [Abstract] [Full Text] [Related]
9. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract] [Full Text] [Related]
11. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Lovell AR; Sawyers J; Bose P
Expert Opin Pharmacother; 2023; 24(11):1307-1316. PubMed ID: 37226798
[TBL] [Abstract] [Full Text] [Related]
12. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
[TBL] [Abstract] [Full Text] [Related]
13. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N; Ando J; Takada S; Yoshida C; Usuki K; Shinagawa A; Ishizawa K; Miyamoto T; Iida H; Dobashi N; Okubo S; Honda H; Soshin T; Nishimura Y; Tsutsui A; Mukai H; Yamamoto K
Jpn J Clin Oncol; 2023 Jun; 53(7):595-603. PubMed ID: 37017320
[TBL] [Abstract] [Full Text] [Related]
14. Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Figueroa-Mora R; Rampotas A; Halperin D; Worth T; Vidler J; Melotti D; Ferguson P; Elmusharaf N; Preston G; Furtado M; Dungarwalla M; Gohill S; Patten P; Kennedy B; Eyre TA; Schuh A; Fox CP; Munir T; Martinez-Calle N
Br J Haematol; 2023 Jul; 202(1):48-53. PubMed ID: 36951278
[TBL] [Abstract] [Full Text] [Related]
15. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA; Al Malki MM; Asch AS; Wang ES; Jurcic JG; Bradley TJ; Flinn IW; Pollyea DA; Kambhampati S; Tanaka TN; Zeidner JF; Garcia-Manero G; Jeyakumar D; Komrokji R; Lancet J; Kantarjian HM; Gu L; Zhang Y; Tan A; Chao M; O'Hear C; Ramsingh G; Lal I; Vyas P; Daver NG
J Clin Oncol; 2023 May; 41(15):2815-2826. PubMed ID: 36888930
[TBL] [Abstract] [Full Text] [Related]
16. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
[TBL] [Abstract] [Full Text] [Related]
17. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
[TBL] [Abstract] [Full Text] [Related]
18. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract] [Full Text] [Related]
19. Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.
Abernathy KM; Perciavalle MA; Gatwood KS; Chen H; Zakhari MM; Byrne M
J Oncol Pharm Pract; 2023 Sep; 29(6):1326-1333. PubMed ID: 35946111
[TBL] [Abstract] [Full Text] [Related]
20. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
[TBL] [Abstract] [Full Text] [Related]
[Next]
